UK Pricing Scheme Negotiations Should Include Broader Representation
Generics and biosimilars manufacturers and patients should have greater influence on UK pricing scheme negotiations.
Generics and biosimilars manufacturers and patients should have greater influence on UK pricing scheme negotiations.